VOLITIONRX LTD (VNRX)
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Medical - Devices
VolitionRX Ltd
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.2030 | 0.2030 | 0.1805 | 0.1887 | 3,098,475 |
| Nov 16, 2026 | 0.2290 | 0.2290 | 0.1902 | 0.1998 | 4,645,917 |
| Nov 13, 2026 | 0.1997 | 0.2420 | 0.1935 | 0.2300 | 56,935,764 |
| Nov 12, 2026 | 0.2000 | 0.2090 | 0.1825 | 0.1845 | 995,894 |
| Nov 11, 2026 | 0.1933 | 0.2036 | 0.1880 | 0.2036 | 681,852 |
| Nov 10, 2026 | 0.2050 | 0.2100 | 0.1782 | 0.1844 | 757,965 |
| Nov 9, 2026 | 0.1959 | 0.2049 | 0.1939 | 0.2000 | 401,469 |
| Nov 6, 2026 | 0.1902 | 0.2000 | 0.1885 | 0.1959 | 468,083 |
| Nov 5, 2026 | 0.2077 | 0.2099 | 0.1832 | 0.1890 | 563,004 |
| Nov 4, 2026 | 0.1948 | 0.2040 | 0.1948 | 0.2031 | 397,971 |
| Nov 3, 2026 | 0.2112 | 0.2139 | 0.1865 | 0.1930 | 850,519 |
| Nov 2, 2026 | 0.2001 | 0.2200 | 0.1950 | 0.2101 | 1,264,289 |
| Oct 30, 2026 | 0.2000 | 0.2003 | 0.1830 | 0.1953 | 1,063,275 |
| Oct 29, 2026 | 0.1843 | 0.2000 | 0.1730 | 0.1975 | 1,093,345 |
| Oct 28, 2026 | 0.1900 | 0.1924 | 0.1707 | 0.1818 | 1,245,301 |
| Oct 27, 2026 | 0.1900 | 0.1927 | 0.1601 | 0.1850 | 3,975,656 |
| Oct 26, 2026 | 0.1750 | 0.1804 | 0.1739 | 0.1786 | 610,916 |
| Oct 23, 2026 | 0.1652 | 0.1783 | 0.1652 | 0.1741 | 509,191 |
| Oct 22, 2026 | 0.1652 | 0.1710 | 0.1564 | 0.1691 | 1,677,045 |
| Oct 21, 2026 | 0.1700 | 0.1726 | 0.1642 | 0.1664 | 494,725 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Group Chief Marketing Officer | Grant/Award | 12.0K | -- | Oct 21, 2026 | |
| Chief Commercial Officer | Automatic Sell | 5.3K | $997.69 | Mar 17, 2026 | |
| Secretary | Automatic Sell | 3.9K | $750.12 | Mar 17, 2026 | |
| Chief Scientific Officer | Automatic Sell | 5.3K | $1.0K | Mar 17, 2026 | |
| GC - Volition Diagnostics | Automatic Sell | 7.0K | $1.3K | Mar 17, 2026 | |
| Secretary | Automatic Sell | 3.3K | $707.373 | Mar 1, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Lagoda Investment Management, L.P. | 1.7M | 4.6% | 13F |
Lagoda Investment Management, L.P. · also on 13F· joint filing· filed Sep 2026 | 1.5M+171.1K via warrants | 4.6% | 13D |
LUMINUS MANAGEMENT LLC | 425.4K | 1.2% | 13F |
Armistice Capital, LLC · may incl. warrants· filed Feb 2026 | 322.5K | 0.9% | 13G |
Cameron Reynolds · may incl. warrants· stale · filed Feb 2024 | 143.4K | 0.4% | 13D |
Quadrant Private Wealth Management, LLC | 85.0K | 0.2% | 13F |
STILL TIMOTHY I Director | 81.3K | 0.2% | FORM 4 |
Miller Financial Services LLC | 71.0K | 0.2% | 13F |
Innes Guy Archibald Director | 62.6K | 0.2% | FORM 4 |
UBS Group AG | 50.9K | 0.1% | 13F |
Insiders
- Batchelor Ann-LouiseGroup Chief Marketing Officer
- Forterre GaelChief Commercial Officer
- Rootsaert Rodney GerardSecretary
- Micallef Jacob VincentChief Scientific Officer
- Plummer NicholasGC - Volition Diagnostics
- Kway JasmineCEO - Singapore Volition
- Hughes TerigChief Financial Officer
- Reynolds Cameron JohnPresident and CEO
- Innes Guy ArchibaldDirector
- Nguyen KimDirector
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
based on 36.08M shares outstanding
30d Avg
3.80M
60d Avg
2.81M
90d Avg
9.68M
Signal8's dilution snapshot of VNRX as of Sep 30, 2026 records an effective S-3 shelf registration (effective Sep 9, 2026), an at-the-market sales agreement dated Apr 22, 2025, 19 outstanding warrant series and a registered direct offering closed Jun 9, 2026, from SEC filings. VolitionRX Ltd (NYSE: VNRX) traded at $0.1887 on Nov 17, 2026, down 5.56% from the previous close of $0.1998. 52-week range: $0.1564 to $7.73. The company is in the Healthcare sector (Medical - Devices).